AnaptysBio Inc (ANAB)

[gfp927z]

HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---